CEL-SCI Corp (CVM) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.57 (+5.37%), Market cap $0.02B, 52-week low–high $1.19 ~ $13.04.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the comp
Financial statements, price targets, institutional (13F) holdings and related news for CEL-SCI Corp are updated in real time on BlackAll Trade.
CEL-SCI Corp trades at $1.57 (+5.37%). Real-time quotes and charts are available on BlackAll Trade.
CEL-SCI Corp has a market cap of about $0.02B.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's l